- Home
- GRFS
GRFS
Grifols S.A.
as 01-17-2025 4:00pm EST
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
| Founded: | 1940 | Country: | Spain |
| Employees: | N/A | City: | N/A |
| Market Cap: | 5.5B | IPO Year: | 2006 |
| Target Price: | N/A | AVG Volume (30 days): | 704.7K |
| Analyst Decision: | Strong Sell | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.30 - $9.96 | Next Earning Date: | 01-01-0001 |
| Revenue: | $7,814,096,584 | Revenue Growth: | 7.21% |
| Revenue Growth (this year): | 9.31% | Revenue Growth (next year): | 7.44% |
Latest Grifols S.A. News
GRFS Breaking Stock News: Dive into GRFS Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Grifols Gets $21 Million Grant to Identify Early Parkinson's Disease Biomarkers
GlobeNewswire
5 days ago
Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson’s Disease
Reuters
5 days ago
Mason Capital complains about Grifols' transparency to Spanish regulator
Simply Wall St.
17 days ago
Exploring Three High Growth Tech Stocks For Future Potential
Bloomberg
a month ago
Grifols’ Worst-Ever Year Can’t Derail Analyst Calls to Buy
Bloomberg
a month ago
Grifols Keeps Door Open to Brookfield With Special Bond Term
MT Newswires
a month ago
Sector Update: Health Care Stocks Retreat Late Afternoon
MT Newswires
a month ago
Sector Update: Health Care
Compare GRFS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GRFS Grifols S.A. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.